Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4081/monaldi.2020.1592 http://scihub22266oqcxt.onion/10.4081/monaldi.2020.1592 33059413!?!33059413 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33059413&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Monaldi+Arch+Chest+Dis 2020 ; 90 (4): ? Nephropedia Template TP {{tp|p=33059413|t=2020. Management and outcomes of patients hospitalized with severe COVID-19 at a tertiary care center in midwestern United States |pdf=|usr=}}{{33059413}} gab.com Text Management and outcomes of patients hospitalized with severe COVID-19 at a tertiary care center in midwestern United States JO: Monaldi Arch Chest Dis http://www.kidney.de/pget.php?&tw=1&pmid=33059413 #FOAvip Knowledge of treatment regimens and outcomes for novel coronavirus disease 2019 (COVID-19) is evolving. Recent studies have reported mortality rates ranging from 39-50% among hospitalized patients with COVID-19. We report our experience ofmanagement and outcomes of hospitalized patients with COVID-19 at a large tertiary-care center in Midwestern United States. Of 658 patients presenting to our tertiary care center, 217 needed hospitalization, majority (77%) of whom were severely sick requiring admission to the intensive care unit (ICU). All received corticosteroids, and 78% of the patients received tocilizumab. More than two-thirds of the patients received anticoagulation and 80% of patients in the ICU had prone-positioning. The median duration of hospitalization was 12 days (interquartile range, 8 to16), median duration of intensive care unit stay was 7 days (interquartile range, 5 to 9) and requirement of mechanical ventilation was 6 days (interquartile range, 5 to 8) in our cohort. Of the 217 patients, 27 died (12% mortality). The majority of our patients received corticosteroids, tocilizumab, anticoagulation and prone positioning. While higher mortality rates of >30% have been reported in various studies among hospitalized patients with COVID-19, the majority of hospitalized patients in our cohort survived with a low mortality rate. The majority of our patients received corticosteroids, tocilizumab, anticoagulation and prone positioning. While higher mortality rates of >30% have been reported in various studies among hospitalized patients with COVID-19, the majority of hospitalized patients in our cohort survived with a low mortality rate. Twit Text FOAVip Management and outcomes of patients hospitalized with severe COVID-19 at a tertiary care center in midwestern United States ????Monaldi Arch Chest Dis http://www.kidney.de/pget.php?&tw=1&pmid=33059413 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33059413 #FOAvip English Wikipedia <ref>{{Cite pmid|33059413}}</ref> Management and outcomes of patients hospitalized with severe COVID-19 at a tertiary care center in midwestern United States #MMPMID33059413 Gupta S; Kaushik A; Gupta J Monaldi Arch Chest Dis 2020[Oct]; 90 (4): ? PMID33059413show ga Knowledge of treatment regimens and outcomes for novel coronavirus disease 2019 (COVID-19) is evolving. Recent studies have reported mortality rates ranging from 39-50% among hospitalized patients with COVID-19. We report our experience ofmanagement and outcomes of hospitalized patients with COVID-19 at a large tertiary-care center in Midwestern United States. Of 658 patients presenting to our tertiary care center, 217 needed hospitalization, majority (77%) of whom were severely sick requiring admission to the intensive care unit (ICU). All received corticosteroids, and 78% of the patients received tocilizumab. More than two-thirds of the patients received anticoagulation and 80% of patients in the ICU had prone-positioning. The median duration of hospitalization was 12 days (interquartile range, 8 to16), median duration of intensive care unit stay was 7 days (interquartile range, 5 to 9) and requirement of mechanical ventilation was 6 days (interquartile range, 5 to 8) in our cohort. Of the 217 patients, 27 died (12% mortality). The majority of our patients received corticosteroids, tocilizumab, anticoagulation and prone positioning. While higher mortality rates of >30% have been reported in various studies among hospitalized patients with COVID-19, the majority of hospitalized patients in our cohort survived with a low mortality rate. The majority of our patients received corticosteroids, tocilizumab, anticoagulation and prone positioning. While higher mortality rates of >30% have been reported in various studies among hospitalized patients with COVID-19, the majority of hospitalized patients in our cohort survived with a low mortality rate. |*Betacoronavirus[MESH] |*Critical Care[MESH] |*Hospitalization[MESH] |*Tertiary Healthcare[MESH] |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH] |Alanine/analogs & derivatives/therapeutic use[MESH] |Antibodies, Monoclonal, Humanized/therapeutic use[MESH] |Anticoagulants/therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19 Serotherapy[MESH] |Coronavirus Infections/diagnosis/drug therapy/epidemiology/*therapy[MESH] |Glucocorticoids/therapeutic use[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Midwestern United States[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/epidemiology/*therapy[MESH] |Respiration, Artificial[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH]Management and outcomes of patients hospitalized with severe COVID-19 (epmc).pdf DeepDyve Pubget Overpricing